Last 12 months
Inside the activity.
7 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 4 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 3 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2017 Filed Jan 2, 2018 23:14 UTC |
Fink Jeffrey ArvinDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000024 · doc4_5175.xml · derivative · entry 3 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common stock · 1,875 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:14 UTC |
Fink Jeffrey ArvinDirector
|
SaleCommon stock | 938 | $3.47 | $3,258.33 |
DisclosureSEC source: 0001638599-18-000024 · doc4_5175.xml · nonDerivative · entry 2 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:14 UTC |
Fink Jeffrey ArvinDirector
|
Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000024 · doc4_5175.xml · nonDerivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 23:50 UTC |
BROWN MORGAN REVP and CFO
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $3.52 Strike: $3.52 | $264,000.00 |
DisclosureSEC source: 0001638599-17-001222 · doc4_5123.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-12-06 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 6, 2018, while the remaining 2/3 of the shares subject to the award have vesting monthly on a prorata basis over the following two years. Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 23:51 UTC |
Patel Mahesh V.Director · CEO, President and Chairman
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $3.52 Strike: $3.52 | $528,000.00 |
DisclosureSEC source: 0001638599-17-001224 · doc4_5125.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO, President and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-12-06 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 6, 2018, while the remaining 2/3 of the shares subject to the award have vesting monthly on a prorata basis over the following two years. Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 23:51 UTC |
Bass Gregory BrooksEVP and Chief Commercial Offic
|
GrantStock Options (Right to Buy) · Derivative | 75,000 | $3.52 Strike: $3.52 | $264,000.00 |
DisclosureSEC source: 0001638599-17-001223 · doc4_5124.xml · derivative · entry 1 Bass Gregory Brooks · CIK 0001696824 · EVP and Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-12-06 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 6, 2018, while the remaining 2/3 of the shares subject to the award have vesting monthly on a prorata basis over the following two years. Read SEC document |
| May 12, 2017 Filed May 12, 2017 20:11 UTC |
Higuchi John W.Director
|
GrantCommon Stock | 17,200 | $3.76 | $64,672.00 |
DisclosureSEC source: 0001638599-17-000440 · doc4_4703.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,248 Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:42 UTC |
BROWN MORGAN REVP and CFO
|
GrantRestricted Stock Unit · Derivative | 37,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000131 · doc4_4496.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:41 UTC |
Mattila JyrkiChief Business Officer
|
GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000129 · doc4_4498.xml · derivative · entry 1 Mattila Jyrki · CIK 0001297318 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:40 UTC |
HILL STEPHEN ADirector
|
GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000128 · doc4_4499.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:41 UTC |
Patel Mahesh V.Director · President and CEO
|
GrantRestricted Stock Unit · Derivative | 60,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000130 · doc4_4497.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:40 UTC |
Fink Jeffrey ArvinDirector
|
GrantRestricted Stock Unit · Derivative | 7,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000127 · doc4_4500.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:39 UTC |
Higuchi John W.Director
|
GrantRestricted Stock Unit · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000125 · doc4_4502.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:39 UTC |
Ono Richard DanaDirector
|
GrantRestricted Stock Unit · Derivative | 7,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000126 · doc4_4501.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common stock · 7,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 10:50 UTC |
Mattila JyrkiChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $3.61 Strike: $3.61 | $144,400.00 |
DisclosureSEC source: 0001638599-16-001676 · doc4_4385.xml · derivative · entry 1 Mattila Jyrki · CIK 0001297318 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2017, while the remaining 2/3 of the shares subject to the award vesting monthly on a prorata basis over the following two years. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 15:48 UTC |
BROWN MORGAN REVP and CFO
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $3.61 Strike: $3.61 | $180,500.00 |
DisclosureSEC source: 0001638599-16-001674 · doc4_4383.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2016-12-07 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2017, while the remaining 2/3 of the shares subject to the award vesting monthly on a prorata basis over the following two years. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 15:49 UTC |
Patel Mahesh V.Director · President, CEO and Chairman
|
GrantStock Option (Right to Buy) · Derivative | 140,000 | $3.61 Strike: $3.61 | $505,400.00 |
DisclosureSEC source: 0001638599-16-001675 · doc4_4384.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2017, while the remaining 2/3 of the shares subject to the award vesting monthly on a prorata basis over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.